These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 15982357

  • 1. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII - clarification of Kogenate inhibitor data.
    Larson P.
    Br J Haematol; 2005 Jul; 130(1):145-6; author reply 146-7. PubMed ID: 15982357
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.
    Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P, ReFacto-AICE Study Group.
    Br J Haematol; 2004 Aug; 126(3):398-404. PubMed ID: 15257713
    [Abstract] [Full Text] [Related]

  • 3. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients.
    Rothschild C, Scharrer I, Brackmann HH, Stieltjes N, Vicariot M, Torchet MF, Effenberger W.
    Haemophilia; 2002 Mar; 8 Suppl 2():10-4. PubMed ID: 11966846
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.
    Aygören-Pürsün E, Scharrer I.
    Thromb Haemost; 1997 Nov; 78(5):1352-6. PubMed ID: 9408018
    [Abstract] [Full Text] [Related]

  • 9. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.
    Yoshioka A, Fukutake K, Takamatsu J, Shirahata A, Kogenate Post-Marketing Surveillance Study Group.
    Int J Hematol; 2006 Aug; 84(2):158-65. PubMed ID: 16926139
    [Abstract] [Full Text] [Related]

  • 10. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?
    Josephson CD, Abshire T.
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):441-6. PubMed ID: 16163220
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.
    Young JH, Liu HC, Hsueh EJ, Huang ML, Peng CT, Chen RL, Maas-Enriquez M, Achilles K.
    Haemophilia; 2009 Jul; 15(4):968-70. PubMed ID: 19473407
    [No Abstract] [Full Text] [Related]

  • 14. Cryoprecipitate in the management of haemophilia in Kenya.
    Taylor JR, Ahluwalia NS, Morrison CJ, Kaviti JN, Cardwell CL.
    East Afr Med J; 1969 Feb; 46(2):121-8. PubMed ID: 5798053
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.